Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Changes For Medtech In 2020: What’s Ahead

Executive Summary

The US Centers for Medicare and Medicaid Services (CMS) has finalized many new coverage policy decisions and coverage rules taking effect in 2020. Medtech Insight provides a review of what industry can expect this year from the Medicare agency.

You may also be interested in...



Final 2020 CMS Outpatient, ASC Payment Rules Broaden Patient Access To Medtech

The US Medicare agency is allowing more device procedures to be conducted at outpatient hospitals and ambulatory surgical centers (ASC), while approving several new devices for passthrough payments for three years under its Outpatient Prospective Payment System and ASC payment system final rule for 2020, released on 1 November.

CMS Releases Final 2020 Home-Health Rule On Payments For Home Infusion-Therapy Equipment

Suppliers of infusion pumps and related supplies for homebound patients are entitled to payment for each visit, including coverage of professional nursing services, training and education, and monitoring of patients, says a US Medicare agency 2020 final rule on home-health benefits released on 1 November.

US Medicare Agency Proposes Expanding Coverage Of Next-Generation Sequencing For Advanced Cancers

There is sufficient evidence to expand coverage of next-generation sequencing (NGS) as a diagnostic test for ovarian, breast or other advanced cancers if certain criteria are met, the Centers for Medicare and Medicaid Services wrote in a 30 October proposed decision memo.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel